How should the management plan be modified for a 50‑year‑old post‑menopausal woman with multiple sclerosis (treated with lymphocyte infusions), controlled hypothyroidism on levothyroxine 50 µg, no other significant comorbidities, who presents with occasional daytime palpitations and an electrocardiogram confirming atrial fibrillation?

SOAP Note: 50-Year-Old Female with New-Onset Atrial Fibrillation

Subjective

• Chief Complaint: Occasional daytime palpitations
• History of Present Illness: 50-year-old post-menopausal female presenting with intermittent palpitations during daytime hours
• Past Medical History:
  • Multiple sclerosis (MS) treated with alemtuzumab (Lemtrada) infusions 4 years ago with excellent response—no new brain or spinal lesions
  • Hypothyroidism on levothyroxine 50 µg daily
  • Post-menopausal status
• Medications: Levothyroxine 50 µg daily
• Social History: No alcohol use
• Review of Systems: Denies chest pain, shortness of breath, syncope, recent acute illness, or symptoms of thyrotoxicosis

Objective

• Vital Signs: [Document heart rate, blood pressure, respiratory rate, temperature]
• Cardiovascular Exam: Irregularly irregular rhythm on auscultation
• EKG: Atrial fibrillation confirmed (absent P waves, irregularly irregular RR intervals)
• Pending Labs: TSH, free T4, CBC, CMP, troponin (to rule out thyrotoxicosis and other precipitants)

Assessment

New-onset atrial fibrillation in a 50-year-old post-menopausal female with controlled hypothyroidism and history of MS treated with alemtuzumab

Key Diagnostic Considerations:

• Thyroid Status Verification: Given the patient is on levothyroxine 50 µg, thyroid function tests are critical—excess thyroid hormone (even subclinical) is associated with increased AF risk, particularly with higher fT4 levels in the highest quartile 1. Levothyroxine overdose can precipitate AF and requires immediate assessment 2.
• Alemtuzumab-Related Thyroid Dysfunction: Alemtuzumab causes thyroid dysfunction in a significant proportion of patients, with Graves' disease being the most common manifestation, followed by hypothyroidism and thyroiditis 3. Up to 70% of hypothyroid patients post-alemtuzumab have positive TSH receptor antibodies (TRAb), with blocking antibodies responsible for nearly half of hypothyroid cases 3. This patient requires TRAb testing even though she appears hypothyroid, as fluctuating thyroid dysfunction can occur 3.
• Age-Related Considerations: In post-menopausal women aged 50, physiological TSH elevation can occur with aging, but this patient's AF requires careful evaluation to avoid both under-treatment and over-treatment with levothyroxine, as both are associated with cardiovascular risks 4.

Plan

1. Immediate Stroke Risk Assessment and Anticoagulation Decision

Calculate CHA₂DS₂-VASc score immediately to determine anticoagulation need 5, 6:

• Age 50 years = 0 points
• Female sex = 1 point
• Total CHA₂DS₂-VASc = 1

For a CHA₂DS₂-VASc score of 1 in a female patient (equivalent to 0 in the original scoring), oral anticoagulation should be considered based on individual characteristics and patient preferences 7. However, given this is new-onset AF and the patient has MS (a chronic inflammatory condition that may confer additional vascular risk), initiate anticoagulation with a direct oral anticoagulant (DOAC) such as apixaban 5 mg twice daily 5, 7. Apixaban is preferred over warfarin due to lower bleeding risk and does not require INR monitoring 6, 7.

2. Rate Control Strategy

Initiate a beta-blocker as first-line therapy for ventricular rate control 8, 5:

• Metoprolol tartrate 25-50 mg twice daily or metoprolol succinate 50-100 mg once daily is recommended as the initial agent 8, 5.
• Beta-blockers are Class I recommendation (highest level) for rate control in AF 5.
• If beta-blockers are contraindicated, use a non-dihydropyridine calcium channel blocker (diltiazem 120-360 mg daily or verapamil 120-360 mg daily) as second-line 8, 5.
• Avoid digoxin as monotherapy in this active 50-year-old patient, as it only controls rate at rest and is ineffective during exercise 6.

3. Thyroid Function Optimization and Monitoring

Order comprehensive thyroid panel immediately:

• TSH, free T4, free T3
• TSH receptor antibodies (TRAb) to assess for alemtuzumab-induced autoimmune thyroid disease 3
• Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies

Levothyroxine dose adjustment strategy:

• If TSH is suppressed (<0.5 mIU/L) or fT4 is in the highest quartile, reduce levothyroxine dose immediately 1, 4. Higher fT4 levels are independently associated with increased AF risk (hazard ratio 1.22 for highest vs. lowest quartile) 1.
• If TSH is elevated (>7 mIU/L) with low fT4, this suggests under-replacement, but avoid aggressive up-titration in the setting of new AF 4.
• Target TSH range: 1.0-2.5 mIU/L in this 50-year-old to minimize cardiovascular risk while maintaining adequate replacement 4.
• Recheck TSH and free T4 in 6-8 weeks after any dose adjustment 9, 10.

Critical pitfall to avoid: In post-menopausal women, over-replacement with levothyroxine increases risk of cardiac arrhythmias and bone turnover 11, 12. Start with conservative dosing and titrate slowly 13, 12.

4. Rhythm Control Consideration

Do not attempt cardioversion or antiarrhythmic therapy until thyroid function is optimized and euthyroid state is confirmed 8, 5. Cardioversion and antiarrhythmic drugs often fail to achieve sustained sinus rhythm while thyroid dysfunction persists 8.

If AF persists after achieving euthyroid state for 3+ months and symptoms remain bothersome despite adequate rate control, consider referral to electrophysiology for catheter ablation 7.

5. Monitoring and Follow-Up

Short-term (2-4 weeks):

• Review thyroid function test results and TRAb status
• Assess adequacy of rate control (target resting heart rate 60-100 bpm, <110 bpm with activity)
• Monitor for symptoms of thyroid dysfunction (palpitations, tremor, heat intolerance suggesting hyperthyroidism; fatigue, weight gain suggesting hypothyroidism) 9
• Ensure anticoagulation adherence and assess bleeding risk

Medium-term (6-8 weeks):

• Recheck TSH and free T4 after any levothyroxine dose adjustment 9, 10
• Repeat EKG to assess rhythm status
• Consider 24-hour Holter monitor if symptoms persist despite rate control

Long-term (3-6 months and annually):

• Annual TSH monitoring once stable on levothyroxine to avoid over-treatment or under-treatment 10, 4
• Continue anticoagulation indefinitely based on CHA₂DS₂-VASc score, not rhythm status 5, 7—even if sinus rhythm is restored, anticoagulation should continue for at least 4 weeks and long-term if thromboembolic risk factors persist 7.
• Monitor for alemtuzumab-related thyroid dysfunction fluctuations, as up to 20% of cases exhibit alternating hyper- and hypothyroidism 3

6. Patient Education

Counsel patient on:

• Anticoagulation importance: Stroke prevention is the primary goal; adherence to apixaban is critical 5, 7
• Levothyroxine timing: Take on empty stomach, 30-60 minutes before breakfast with full glass of water 9. Avoid taking within 4 hours of iron, calcium supplements, or antacids 9.
• Symptoms requiring immediate attention: Rapid or irregular heartbeat, chest pain, shortness of breath, neurological symptoms (stroke warning signs), or signs of thyroid storm (fever, severe tachycardia, altered mental status) 9
• Alemtuzumab-related thyroid monitoring: Lifelong thyroid surveillance is required post-alemtuzumab due to risk of delayed autoimmune thyroid dysfunction 3

7. Specialist Referrals

• Endocrinology referral: For management of alemtuzumab-related thyroid dysfunction and optimization of levothyroxine dosing in the context of AF 3
• Cardiology referral: If rate control is inadequate, symptoms persist, or rhythm control strategy is needed after achieving euthyroid state
• Electrophysiology referral: If AF persists despite euthyroid state and patient desires rhythm control, consider catheter ablation 7

---

Key Management Principles Summary

The diagnosis of atrial fibrillation fundamentally changes this patient's treatment plan in three critical ways:

1. Anticoagulation is now required based on CHA₂DS₂-VASc score to prevent stroke 5, 6, 7
2. Rate control with beta-blockers must be initiated immediately to reduce cardiovascular morbidity 8, 5
3. Levothyroxine dosing requires urgent reassessment and optimization to eliminate thyroid hormone excess as a potential AF trigger, with careful avoidance of both over-replacement (which increases AF risk) and under-replacement (which worsens cardiovascular outcomes) 1, 4

The history of alemtuzumab treatment adds complexity, requiring TRAb testing and long-term thyroid surveillance for fluctuating autoimmune thyroid dysfunction 3.